Orladeyo denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for orladeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Orladeyo as Duplicate Therapy

Aetna may issue a duplicate-therapy denial for Orladeyo (berotralstat) when your records show you are already receiving another oral prophylactic agent for hereditary angioedema (HAE) — most often another plasma kallikrein inhibitor or a bradykinin pathway drug. The insurer's logic is that two preventive agents targeting the same pathway are redundant. This reasoning is frequently incorrect or misapplied: your prescriber may have a documented clinical rationale for the combination or transition, or the prior agent may have already been discontinued.

## Why This Denial Is Appealable

A duplicate-therapy determination is a medical judgment, not a hard formulary rule. Aetna must evaluate the specific clinical context — including whether the "duplicate" drug is still active, whether there is a documented reason for the overlap (cross-taper, inadequate response to the first agent, or tolerability), and whether the prescriber's medical-necessity judgment was considered. Under ERISA §503 and the ACA §2719 external-review framework, you have the right to a full and fair review of any adverse benefit determination.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice. Aetna must decide within 30 days for pre-service denials or 60 days for post-service claims.
• External review (ACA §2719): After exhausting internal appeals (or if Aetna takes longer than allowed), you may request independent external review. The external reviewer's decision is binding on the plan. The window to request external review is generally 4 months from the final internal denial.
• Expedited review: If the standard timeline could seriously jeopardize your health, request expedited internal review (72-hour turnaround) and expedited external review (72 hours).

## Documentation to Gather

1. Diagnosis confirmation — chart notes, genetic testing, or specialist letters confirming HAE diagnosis and attack frequency/severity. 2. Prior-treatment history — dates, agents tried, outcomes, and reason for stopping each prior prophylactic therapy (inadequate control, adverse effects, tolerability). 3. Current medication list — demonstrate whether the alleged "duplicate" agent is actually active or has been discontinued. 4. Prescriber medical-necessity letter — your physician should explain the clinical rationale for Orladeyo specifically, why it is not duplicative in your case, and the expected benefit. 5. Applicable guideline support — reference the relevant HAE guideline organization (e.g., US Hereditary Angioedema Association guidelines) generically to contextualize the prescriber's decision.

## Criteria-Mapping Structure

Obtain Aetna's published coverage policy for Orladeyo (berotralstat) and copy each listed requirement into a table. For each requirement, document the exact chart fact that satisfies it. Common criteria categories include: confirmed HAE diagnosis (with type), documented attack frequency, prior treatment history with outcomes, and prescriber attestation. For each, your appeal letter should quote the policy language and then cite the specific chart entry (date, note, test result) that meets it.

If the denial was triggered by an automated duplicate-drug flag rather than clinical review, your prescriber's letter should request that a physician-level reviewer assess whether the clinical circumstances genuinely constitute duplication.